Search research articles
Contact Us
Filters
Showing results (301-310 of 383) with videos related to
Page
of 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2008
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Giuseppe Viale, Anita Giobbie-Hurder, Meredith M Regan, et al.
JAMA Oncology
|
June 1, 2018
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial
Heikki Joensuu, Judith Fraser, Hans Wildiers, et al.
Current Medical Research and Opinion
|
August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy
Mario Campone, J Thaddeus Beck, Michael Gnant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2023
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Hanne Lefrère, Kat Moore, Giuseppe Floris, et al.
Breast Cancer Research and Treatment
|
November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Brian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
The New England Journal of Medicine
|
December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study
Frédéric Amant, Gunter von Minckwitz, Sileny N Han, et al.
Breast Cancer Research and Treatment
|
February 12, 2008
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
Ben Van Calster, Isabelle Vanden Bempt, Maria Drijkoningen, et al.
NPJ Breast Cancer
|
March 21, 2024
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, et al.
Page
of 39
Search research articles
Search
Showing results (301-310 of 383) with videos related to
Sort By:
Page
of 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2008
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Giuseppe Viale, Anita Giobbie-Hurder, Meredith M Regan, et al.
JAMA Oncology
|
June 1, 2018
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial
Heikki Joensuu, Judith Fraser, Hans Wildiers, et al.
Current Medical Research and Opinion
|
August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy
Mario Campone, J Thaddeus Beck, Michael Gnant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2023
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Hanne Lefrère, Kat Moore, Giuseppe Floris, et al.
Breast Cancer Research and Treatment
|
November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Brian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
The New England Journal of Medicine
|
December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study
Frédéric Amant, Gunter von Minckwitz, Sileny N Han, et al.
Breast Cancer Research and Treatment
|
February 12, 2008
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
Ben Van Calster, Isabelle Vanden Bempt, Maria Drijkoningen, et al.
NPJ Breast Cancer
|
March 21, 2024
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, et al.
Page
of 39